Want to see HK:8189 full AI Analyst Report?
Total Valuation
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has a market cap or net worth of HK$522.81M. The enterprise value is HK$350.33M.
Market CapHK$522.81M
Enterprise ValueHK$350.33M
Share Statistics
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,436,400,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s return on equity (ROE) is -7.23 and return on invested capital (ROIC) is -20.64%.
Return on Equity (ROE)-7.23
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-20.64%
Return on Capital Employed (ROCE)-1.81
Revenue Per Employee1.87M
Profits Per Employee-413.68K
Employee Count273
Asset Turnover1.92
Inventory Turnover3.34
Valuation Ratios
The current PE Ratio of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H is ―. Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s PEG ratio is -0.04.
PE Ratio―
PS Ratio1.12
PB Ratio46.59
Price to FCF-9.07
Price to Operating Cash Flow0.37
PEG Ratio-0.04
Income Statement
In the last 12 months, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H had revenue of 509.43M and earned -88.47M in profits. Earnings per share was -0.04.
Revenue509.43M
Gross Profit34.75M
Operating Income-23.57M
Pretax Income-110.01M
Net Income-88.47M
EBITDA-14.08M
Earnings Per Share (EPS)-0.04
Cash Flow
In the last 12 months, operating cash flow was 119.16M and capital expenditures -13.09M, giving a free cash flow of 106.08M billion.
Operating Cash Flow119.16M
Free Cash Flow106.08M
Free Cash Flow per Share0.07
Dividends & Yields
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.11
52-Week Price Change-38.75%
50-Day Moving Average0.24
200-Day Moving Average0.25
Relative Strength Index (RSI)41.25
Average Volume (3m)1.18M
Important Dates
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H upcoming earnings date is Apr 1, 2027, TBA (Not Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateApr 1, 2027
Ex-Dividend Date―
Financial Position
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H as a current ratio of 0.75, with Debt / Equity ratio of 485.06%
Current Ratio0.75
Quick Ratio0.19
Debt to Market Cap0.17
Net Debt to EBITDA-5.72
Interest Coverage Ratio-6.39
Taxes
In the past 12 months, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has paid 593.33K in taxes.
Income Tax593.33K
Effective Tax Rate>-0.01
Enterprise Valuation
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H EV to EBITDA ratio is -46.20, with an EV/FCF ratio of -10.35.
EV to Sales1.28
EV to EBITDA-46.20
EV to Free Cash Flow-10.35
EV to Operating Cash Flow-11.91
Balance Sheet
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has HK$65.29M in cash and marketable securities with HK$108.79M in debt, giving a net cash position of -HK$43.50M billion.
Cash & Marketable SecuritiesHK$65.29M
Total DebtHK$108.79M
Net Cash-HK$43.50M
Net Cash Per Share-HK$0.03
Tangible Book Value Per Share>-HK$0.01
Margins
Gross margin is 8.02%, with operating margin of -4.63%, and net profit margin of -17.37%.
Gross Margin8.02%
Operating Margin-4.63%
Pretax Margin-21.60%
Net Profit Margin-17.37%
EBITDA Margin-2.76%
EBIT Margin-4.63%
Analyst Forecast
The average price target for Tianjin TEDA Biomedical Engineering Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast53.32%
EPS Growth Forecast-122.35%